SomaLogic (NASDAQ:SLGC – Get Rating) is one of 41 publicly-traded companies in the "Commercial physical research" industry, but how does it contrast to its peers? We will compare SomaLogic to similar companies based on the strength of its earnings, risk, institutional ownership, dividends, profitability, analyst recommendations and valuation.

Profitability

This table compares SomaLogic and its peers' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares SomaLogic and its peers top-line revenue, earnings per share (EPS) and valuation.

Institutional & Insider Ownership

59.3% of SomaLogic shares are held by institutional investors. Comparatively, 58.4% of shares of all "Commercial physical research" companies are held by institutional investors. 12.9% of SomaLogic shares are held by insiders. Comparatively, 11.9% of shares of all "Commercial physical research" companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for SomaLogic and its peers, as reported by MarketBeat.

SomaLogic currently has a consensus target price of $12.20, suggesting a potential upside of 249.57%. As a group, "Commercial physical research" companies have a potential upside of 46.17%. Given SomaLogic's stronger consensus rating and higher probable upside, research analysts plainly believe SomaLogic is more favorable than its peers.

Volatility and Risk

SomaLogic has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, SomaLogic's peers have a beta of 5.23, indicating that their average stock price is 423% more volatile than the S&P 500.

Summary

SomaLogic peers beat SomaLogic on 7 of the 13 factors compared.

SomaLogic Company Profile

(Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.